These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 37535864)

  • 21. Evaluating tobacco industry 'transformation': a proposed rubric and analysis.
    Edwards R; Hoek J; Karreman N; Gilmore A
    Tob Control; 2022 Mar; 31(2):313-321. PubMed ID: 35241605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Reduced-Nicotine Cigarettes Across Regulatory Environments in the Experimental Tobacco Marketplace: A Randomized Trial.
    Kaplan BA; Koffarnus MN; Franck CT; Bickel WK
    Nicotine Tob Res; 2021 Jun; 23(7):1123-1132. PubMed ID: 33165612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Philip Morris International's Formula 1 Sponsorship-Linked Marketing: Transformation From Marlboro to Mission Winnow.
    Dewhirst T; Lee WB; Czaplicki L
    Nicotine Tob Res; 2023 Nov; 25(12):1838-1846. PubMed ID: 37702346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Explaining the discontinuation of a non-tobacco nicotine project at Philip Morris: obstacles to innovation.
    Cahn Z; Eckhaus L
    J Public Health Policy; 2018 May; 39(2):131-142. PubMed ID: 29531301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What Is Accounting for the Rapid Decline in Cigarette Sales in Japan?
    Cummings KM; Nahhas GJ; Sweanor DT
    Int J Environ Res Public Health; 2020 May; 17(10):. PubMed ID: 32443663
    [TBL] [Abstract][Full Text] [Related]  

  • 26. E-cigarettes and Weight Loss-Product Design Innovation Insights From Industry Patents.
    Singh H; Kennedy RD; Lagasse LP; Czaplicki LM; Cohen JE
    Nicotine Tob Res; 2018 Jul; 20(8):1010-1014. PubMed ID: 28525609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nicotine pharmacokinetics and subjective responses after using nicotine pouches with different nicotine levels compared to combustible cigarettes and moist smokeless tobacco in adult tobacco users.
    Liu J; Rensch J; Wang J; Jin X; Vansickel A; Edmiston J; Sarkar M
    Psychopharmacology (Berl); 2022 Sep; 239(9):2863-2873. PubMed ID: 35869988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. E-cigarette Unit Sales by Product and Flavor Type, and Top-Selling Brands, United States, 2020-2022.
    Ali FRM; Seidenberg AB; Crane E; Seaman E; Tynan MA; Marynak K
    MMWR Morb Mortal Wkly Rep; 2023 Jun; 72(25):672-677. PubMed ID: 37347717
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Promoting healthier options? Inside the branding of light cigarettes and targeting youth in Brazil.
    Crosbie E; Hartman J; Tran B; Bialous S
    Glob Public Health; 2022; 17(9):1913-1923. PubMed ID: 34852728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. No sisyphean task: how the FDA can regulate electronic cigarettes.
    Paradise J
    Yale J Health Policy Law Ethics; 2013; 13(2):326-74. PubMed ID: 24340824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trends in US E-cigarette Sales and Prices by Nicotine Strength, Overall and by Product and Flavor Type, 2017-2022.
    Ali FRM; Seaman EL; Crane E; Schillo B; King BA
    Nicotine Tob Res; 2023 Apr; 25(5):1052-1056. PubMed ID: 36580384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Public Health Policies on E-Cigarettes.
    Bhalerao A; Sivandzade F; Archie SR; Cucullo L
    Curr Cardiol Rep; 2019 Aug; 21(10):111. PubMed ID: 31463564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comprehensive examination of own- and cross-price elasticities of tobacco and nicotine replacement products in the U.S.
    Huang J; Gwarnicki C; Xu X; Caraballo RS; Wada R; Chaloupka FJ
    Prev Med; 2018 Dec; 117():107-114. PubMed ID: 29684418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A New Ingenious Enemy: Heat-Not-Burn Products.
    Kim SC; Friedman TC
    Tob Use Insights; 2022; 15():1179173X221076419. PubMed ID: 35237081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trends in Nicotine Strength in Electronic Cigarettes Sold in the United States by Flavor, Product Type, and Manufacturer, 2017-2022.
    Wang X; Ghimire R; Shrestha SS; Borowiecki M; Emery S; Trivers KF
    Nicotine Tob Res; 2023 Jun; 25(7):1355-1360. PubMed ID: 36929029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. United States Food and Drug Administration's authorization of reduced exposure claims for IQOS
    Eckford R; Severini G; Sebrié EM; Muggli ME; Beem A; Rosen D; Crosbie E
    Rev Panam Salud Publica; 2022; 46():e155. PubMed ID: 36245905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of industry data on pulmonary and immunosuppressive effects of IQOS.
    Moazed F; Chun L; Matthay MA; Calfee CS; Gotts J
    Tob Control; 2018 Nov; 27(Suppl 1):s20-s25. PubMed ID: 30158203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tobacco industry messaging around harm: Narrative framing in PMI and BAT press releases and annual reports 2011 to 2021.
    Fitzpatrick I; Dance S; Silver K; Violini M; Hird TR
    Front Public Health; 2022; 10():958354. PubMed ID: 36330126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Informing iQOS Regulations in the United States: A Synthesis of What We Know.
    Berg CJ; Bar-Zeev Y; Levine H
    Sage Open; 2020; 10(1):. PubMed ID: 32719733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cue Reactivity Effects of Heated Tobacco Product Use in Current, Former, and Never Smokers in the United States.
    Brett EI; Lee Z; Leavens ELS; Fridberg DJ; King AC
    Nicotine Tob Res; 2023 Apr; 25(5):1014-1021. PubMed ID: 36205373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.